Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function

These 2 randomized clinical trials compare the efficacy and safety of 2 doses of the autotaxin inhibitor ziritaxestat vs placebo in patients with idiopathic pul

Related Keywords

Helsinki , Eteläuomen Läi , Finland , United States , America , Los Angeles , Vicore Pharma , Devpro Biopharma , Astrazeneca Daiichi Sankyo , Redx Pharma , Tobym Maher , Shionogi Co Ltd , Care Center Network , Janssen Pharmaceuticals , Kinevant Sciences , Bristol Myers Squibb , Puretech Health , Novartis , Gilead Sciences , Pfizer , Boehringer Ingelheim , Thyron Pharmaceuticals , Keck School Of Medicine , Institute Inc , Source Imaging Consortium , National Scleroderma Foundation , Pulmonary Fibrosis Foundation , Astrazeneca , Genentech , Regeneron Pharmaceuticals , Glaxosmithkline , Daewoong Pharmaceutical Co , University Of Southern California , Group Information , Latin America , Middle East , North America , Respiratory Questionnaire , Eligibility Criteria , Secondary Outcomes , Pharmacodynamic Assessments , Baseline Characteristics , Annual Rate , Cause Mortality , Target Engagement , Keck School , Southern California , Van Den Blink , Interest Disclosures , Galecto Biotech , Blade Therapeutics , Pliant Therapeutics , Huitai Biomedicine , Open Source Imaging Consortium , Third Pole Therapeutics , Translate Bio , Dispersol Technologies , National Scleroderma , United Therapeutics , Care Center , Chiesi Farmaceutici Spa , Resolution Therapeutics , Nordic Biosciences , Pulmonary Fibrosis , Hoffmann La Roche , Horizon Therapeutics , Trevi Therapeutics ,